We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Cardiac Valve Pathogens Detected by Multiplex Assay

By LabMedica International staff writers
Posted on 14 Jan 2014
Infective endocarditis (IE) is a life-threatening condition burdened by high mortality, and gram-positive cocci account for the majority of the cases. More...


Blood culture represents a cornerstone for the microbiological diagnosis of IE, but it can be negative in a substantial number of patients. Similarly, culture of excised cardiac valves can be burdened by a considerable number of false negative results, mostly in patients under antibiotic therapy, or by false positive results, due to contamination.

Microbiologists at the University of Perugia (Italy) carried out a proof of concept study using a commercially available multiplex real-time polymerase chain reaction (PCR) for the detection of pathogens in cardiac valves from patients with infective endocarditis. Between June 2011 and January 2013, 20 cardiac valves, 11 mitral and 9 aortic excised from an equal number of patients with definite IE diagnosis of known etiology were tested by conventional culture and the real-time PCR test. Five aortic valves excised from non-IE patients, affected by noninfective cardiac complications, were included in the study as controls. Mean age of the patients was 64.2 years and all patients were on antimicrobial therapy during sampling.

All excised valves were examined with Gram stain and inoculated into culture media. The commercially available SeptiFast real-time-PCR system (Roche Molecular Systems; Mannheim, Germany) was evaluated as a diagnostic tool for IE and was performed in Roche Diagnostics’ LightCycler instrument. An organism detected by SeptiFast (SF) test was considered true pathogen if it coincided with the infectious agent previously isolated from blood culture, collected from the same IE patient.

The SeptiFast test gave a positive result in 19 out of 20 valves from patients with IE, and a negative result in all the five valves from non-IE patients. In all cases, the organism detected by the test was concordant with the known etiologic agent and Gram staining. Culture was positive in 3 out of 20 valves from IE patients, for microorganisms matching those previously isolated from blood culture and was negative in all valves from non-IE patients, and therefore culture sensitivity was only 15.8%, and specificity was 100%. Gram staining was positive in 16 valves from IE patients, and negative in all non-IE patients.

The authors concluded that the SeptiFast (SF) assay can be used on culture-negative heart valve tissues, excised from patients with IE, showing sensitivity and negative predicative value (NPV) higher than culture, with the same high specificity and positive predictive value (PPV). In cases of SF positive for coagulase-negative staphylococci (CoNS) or streptococci, a DNA sequencing of the amplicons would be required to identify the pathogen at the species level. In case of negative SF result, it would be advisable to test cardiac valves by PCR procedures specific for uncommon infectious agents of IE. The study was published on December 21, 2013, in the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

University of Perugia
Roche Molecular Systems 



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Electrolyte Analyzer
BKE-B
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.